PulmoGate Raises ¥330M Seed
PulmoGate raises ¥330 million in a seed round led by Beyond Next Ventures to advance its medical AI platform for interstitial lung disease management.
PulmoGate Raises ¥330M Seed
PulmoGate, a medical AI startup based in Nagoya, Japan, has raised approximately ¥330 million in a seed round. The company focuses on developing AI-driven solutions to improve the diagnosis, treatment, and rehabilitation of interstitial lung disease.
Investors
The round was led by Beyond Next Ventures Co., Ltd. Additional investors include Teijin Pharma Limited, Mitsubishi UFJ Capital Co., Ltd., and STATION Ai Central Japan No. 2 Investment Limited Partnership (managed by STATION Ai Co., Ltd. and Deepcore Co., Ltd.).
PulmoGate Use of Funds
PulmoGate plans to use the capital to scale its online second opinion platform for interstitial lung disease utilizing remote medical diagnosis and discussion. Additionally, the company will invest in the development, clinical evaluation, and regulatory compliance of diagnostic and treatment strategy AI, as well as its home-based patient monitoring and rehabilitation support app.
About PulmoGate
PulmoGate is a medical AI company originating from Nagoya University. The company focuses on developing technology for interstitial lung disease, aiming to improve diagnosis, treatment decisions, and patient monitoring through AI and remote medical collaboration. PulmoGate's mission is to shed light on medical challenges that humanity has yet to see and solve them with the collective intelligence of people and technology.
Funding Details
Company Website: https://pulmogate.com
Company: PulmoGate
Raised: ¥330M
Round: Seed
Funding Date: November 2026
Lead Investor: Beyond Next Ventures Co., Ltd.
Additional Investors: Teijin Pharma Limited, Mitsubishi UFJ Capital Co., Ltd., STATION Ai Central Japan No. 2 Investment Limited Partnership
Software Category: Healthcare AI
Source: https://prtimes.jp/main/html/rd/p/000000003.000191902.html